Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its third quarter 2014 and recent business activities. The company continued to grow sales of LINZESS, advance its pipeline of investigational medicines for gastrointestinal (GI) disorders, and manage expenses.
“During the third quarter, we made significant progress across all aspects of our business. With continued strong prescription demand, we now expect the LINZESS brand to be profitable going forward and to deliver significant cash flows to the company into at least 2031,” said Peter Hecht, chief executive officer of Ironwood.
Help employers find you! Check out all the jobs and post your resume.
“During the third quarter, we made significant progress across all aspects of our business. With continued strong prescription demand, we now expect the LINZESS brand to be profitable going forward and to deliver significant cash flows to the company into at least 2031,” said Peter Hecht, chief executive officer of Ironwood.
Help employers find you! Check out all the jobs and post your resume.